Ying Luo, Chen Li, Yuanchen Niu, Shuanzhi Wu, Jingyuan Tian, Zhiqin Hu, Jin He, Zhixin Zhang, Haiyan Liu, Yongmei Li, Tenghua Wang, Yi Fang
BACKGROUND: To evaluate the efficacy and safety of pomalidomide in combination treatment of relapsed/refractory multiple myeloma (RRMM). METHODS: Published clinical trials were searched in the Cochrane Library, PubMed, EMBASE to February 2023. The literature was screened and evaluated according to the inclusion criteria, and the data were analyzed by a random effect model. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS) and full grade or ≥ 3 adverse events (AEs) were the outcomes...
February 29, 2024: Expert Review of Hematology
Drew Provan, Jecko Thachil, María Teresa Álvarez Román
INTRODUCTION: Immune thrombocytopenia (ITP), a disease that commonly presents with an increased risk of bleeding, can also paradoxically produce an increased risk of thromboembolic events. The risk of thromboembolism can be associated with patient-related factors (e.g. co-morbidities, age and history of thrombosis), disease-related factors (e.g. a greater proportion of younger, more reactive platelets, and the presence of microparticles and pro-inflammatory cytokines) and treatment-related factors (e...
February 19, 2024: Expert Review of Hematology
Inés Gómez Seguí, María Eva Mingot Castellano, Cristina Pascual Izquierdo, Javier de la Rubia
INTRODUCTION: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening disorder. Caplacizumab has been the latest drug incorporated into the initial treatment of acute episodes, allowing for a faster platelet recovery and a decrease in refractoriness, exacerbation, thromboembolic events and mortality. However, caplacizumab also associates a bleeding risk and higher treatment costs, which prevent many centers from using it universally. AREAS COVERED: The studies that included iTTP and/or caplacizumab till date were selected for this review using PubMed, MEDLINE platforms...
February 14, 2024: Expert Review of Hematology
Raul Cordoba, Joaquín Sánchez-García, Eva Domingo-Domenech, Javier López Jiménez, Antonio Martínez Pozo, Cecilia Carpio, Ángeles Bendaña, Ana Julia González, Sonia González de Villambrosia, José Gómez Codina, Belén Navarro, Guillermo Rodríguez, Andrea Naves, Lourdes Baeza, Alejandro Martín García-Sancho
BACKGROUND: An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of18 F-FDG-PET/CT for survival following first-line treatment in PTCL patients...
February 7, 2024: Expert Review of Hematology
Yang Liu, Bo Li, Xiaomin Chen, Hao Xiong, Chunlan Huang
INTRODUCTION: Immunomodulatory drugs (IMiDs) are widely used in the management of newly diagnosed and relapsed/refractory multiple myeloma patients. These agents show their potential effect on myeloma bone disease(MBD),including inhibition of osteoclasts activity and effects on osteoblasts differentiation. It is uncertain whether these effects are direct, which may have an impact on bone formation markers when combined with proteasome inhibitors. AREAS COVERED: This review summarizes the available evidence on the role of IMiDs in microenvironment regulation and potential effects on bone metabolism...
February 6, 2024: Expert Review of Hematology
Kun Xu, Xian-Xu Zhuang, Xiao-Wei Shi
BACKGROUND: This study aimed to explore the effect and mechanism of SCN5A overcoming ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR) in acute myeloid leukemia (AML) through promoting apoptosis. RESEARCH DESIGN AND METHODS: The tissues derived from AML patients were divided into Sensitive group and Resistance group according to the presence of drug-resistance. Human AML cell line HL-60 and drug-resistant strain HL-60/ADR were divided into HL-60/ADR-vector group, HL-60/ADR-SCN5A group, HL-60-vector group and HL-60-SCN5A group...
January 17, 2024: Expert Review of Hematology
Francesco Marongiu, Maria Filomena Ruberto, Silvia Marongiu, Antonella Mameli, Doris Barcellona
INTRODUCTION: Thrombophilia testing (TT) is a laboratory procedure designed to detect the risk factors involved in the pathogenesis of vascular occlusions. The role of TT is also controversial because it has a limited impact on the choice and duration of antithrombotic treatments. AREAS COVERED: We reviewed, by examining MEDLINE up to October 2023. Accepted and not accepted thrombophilia markers are discussed along with the appropriateness or not of prescribing TT in several conditions such as: provoked and unprovoked venous thromboembolism (VTE), women who are planning a pregnancy whose relatives had VTE or have a hereditary thrombophilia, before assumption of estro-progestins, after multiple pregnant loss, arterial thrombosis, retinal vein occlusion, and splanchnic vein thrombosis...
January 16, 2024: Expert Review of Hematology
José Carlos Jaime-Pérez, Jesús Daniel Meléndez-Flores, Jorge Valdespino-Valdes, Andrés Gómez-De León, Perla Rocío Colunga-Pedraza, César Homero Gutiérrez-Aguirre, Olga Graciela Cantú-Rodríguez, David Gómez-Almaguer
BACKGROUND: HLA compatibility predicts allogeneic hematopoietic cell transplant (allo-HCT) and graft-versus-host disease (GvHD) outcomes. There is insufficient information regarding GvHD outcomes for outpatient HLA-identical and haploidentical-HCT employing reduced-intensity conditioning (RIC). RESEARCH DESIGN AND METHODS: We compare GvHD outcomes between donor types and report risk factors associated with GvHD. Stem cell source was T-cell replete peripheral blood...
January 16, 2024: Expert Review of Hematology
(no author information available yet)
No abstract text is available yet for this article.
January 10, 2024: Expert Review of Hematology
Yixin Zhai, Ju Hong, Jinhuan Wang, Yanan Jiang, Wenqi Wu, Yangyang Lv, Jing Guo, Linyan Tian, Huimeng Sun, Yuhang Li, Cheng Li, Hongjie Zhan, Zhigang Zhao
OBJECTIVES: This study evaluated the benefits and risks of patients with refractory or relapsed acute lymphocytic leukemia (R/R ALL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and blinatumomab. METHODS: PubMed, Web of Science, Embase, and the Cochrane Library were searched for relevant studies. RESULTS: The pooled complete remission (CR) rate and minimal residual disease (MRD) negative rate were 48%, 31% for blinatumomab, and 86% and 80% for CAR T-cell therapy...
December 22, 2023: Expert Review of Hematology
E Carlos Rodriguez-Merchan
INTRODUCTION: In patients with congenital bleeding disorders suffering from severe ankle arthropathy, when conservative treatment and joint-preserving surgical techniques fail, there are two possible non-joint-preserving options: ankle arthrodesis (AA) and total ankle replacement (TAR). AREAS COVERED: The scope and aim of this article was to analyze the current role of AA and TAR in patients with congenital bleeding disorders suffering from severe ankle arthropathy...
December 22, 2023: Expert Review of Hematology
Ampaiwan Chuansumrit, Theera Ruchutrakul, Nongnuch Sirachainan, Pimpun Kitpoka, Monratta Panuwannakorn, Panyu Panburana, Monthon Suwannuraks, Nantana Sri-Udomporn, Chusak Kijkunasathian, Suphaneewan Jaovisidha, Chirawat Utamakul, Rungrote Natesirinilkul, Bunchoo Pongtanakul, Chanchai Traivaree, Patcharee Komvilaisak, Ekawat Suwantaroj, Darintr Sosothikul, Pantep Angchaisuksiri, Ponlapat Rojnuckarin
INTRODUCTION: Inherited bleeding disorders (IBDs) including hemophilia, von Willebrand disease, platelet disorders, mucocutaneous bleeding disorders and coagulation factor deficiencies are rarely found and under-recognized in low and lower-middle-income countries. Some patients succumbed to serious bleeding without diagnosis and treatment during childhood. AREA COVERED: Diagnosis, management, and prevention should be integrated into the existing health care system...
December 15, 2023: Expert Review of Hematology
Roberto Lúcio Muniz, Ricardo Mesquita Camelo, Maiara Silva Araújo, Mariana Michel Barbosa, Augusto Afonso Guerra, Francisco de Assis Acurcio, Juliana Alvares-Teodoro
BACKGROUND: Emicizumab is a monoclonal antibody approved for prophylaxis against bleeds for people with hemophilia A (PwHA). A systematic review was conducted evaluating the efficacy/effectiveness and the safety of emicizumab as prophylaxis for PwHA compared to prophylaxis with factor VIII (FVIII) or bypassing agents (BPA), respectively in patients without and with inhibitors. RESEARCH DESIGN AND METHODS: Database-directed search strategies were performed in Aug/26/22 and updated in Mar/16/2023...
December 8, 2023: Expert Review of Hematology
Marianna Criscuolo, Nicola Fracchiolla, Francesca Farina, Luisa Verga, Livio Pagano, Alessandro Busca
INTRODUCTION: The recent introduction of targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors, and immunotherapies has improved the cure rate of hematologic patients. The implication of personalized treatment on primary antifungal prophylaxis will be discussed. AREAS COVERED: We reviewed the literature for clinical trials reporting the rate of invasive fungal infections during targeted and cellular therapies and stem cell transplant, and the most recent international guidelines for primary antifungal prophylaxis...
December 4, 2023: Expert Review of Hematology
Nadia Gabarin, Michael Hack, Ryan Revilla, Donald M Arnold, Ishac Nazy
INTRODUCTION: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening prothrombotic disorder first identified following the introduction of adenoviral vector vaccines for COVID-19. The condition is characterized by anti-PF4 antibodies and clinically presents with thrombocytopenia and thrombosis often in unusual anatomical sites. AREAS COVERED: In this review, we discuss the clinical presentation, diagnostic testing, and treatment of VITT...
2024: Expert Review of Hematology
Andrea Boccatonda, Elena Campello, Chiara Simion, Paolo Simioni
INTRODUCTION: both symptomatic and asymptomatic SARS-CoV-2 infections - coined Coronavirus disease 2019 (COVID-19) - have been linked to a higher risk of cardiovascular events after recovery. AREAS COVERED: our review aims to summarize the latest evidence on the increased thrombotic and cardiovascular risk in recovered COVID-19 patients and to examine the pathophysiological mechanisms underlying the interplay among endothelial dysfunction, inflammatory response and coagulation in long-COVID...
November 28, 2023: Expert Review of Hematology
Radovan Kubeš, Martin Stollin, Štěpán Magersky, Maryan Bobelyak, Jan Vaculík, Josef Včelák, Aleš Antonín Kuběna, Jan Loužil, Peter Salaj
BACKGROUND: Patients with hemophilia (PWH) develop hemophilic arthropathy of the major joints due to recurrent hemarthrosis. This study retrospectively estimated the age at which PWH may expect to develop hemophilic arthropathy and undergo joint replacement surgery. RESEARCH DESIGN AND METHODS: Using retrospective data from PWH at a Czech orthopedic center, Kaplan Meier analyses were used to estimate the cumulative proportions of patients with hemophilic arthropathy and undergoing joint replacement surgery as a function of age...
November 28, 2023: Expert Review of Hematology
Wenhui Zhang, Shitong Xie, Rongfeng Fu, Yunfei Chen, Wei Liu, Ting Sun, Mankai Ju, Huiyuan Li, Feng Xue, Lei Zhang, Xiaofan Liu, Renchi Yang
BACKGROUND: There is lacking studies of longitudinally assessment of fatigue and health-related quality of life (HRQoL) among Chinese immune thrombocytopenia (ITP) adults. We aimed to evaluate changes in fatigue and HRQoL and identify the associated factors. METHODS: Patients' characteristics, Functional Assessment of Chronic Illness Therapy (FACIT-F) and the ITP-specific Patient Assessment Questionnaire (ITP-PAQ) scores at admission (T0), at discharge (T1), and three months after discharge (T2) were collected...
November 27, 2023: Expert Review of Hematology
James A Davis, Katelynn Granger, Alex Sakowski, Sara Goodwin, Amanda Herbst, Deidra Smith, Lindsey Hendrickson, Victoria R Nachar
No abstract text is available yet for this article.
November 20, 2023: Expert Review of Hematology
David C Dale, Audrey Anna Bolyard, Vahagn Makaryan
INTRODUCTION: Severe chronic neutropenia, i.e. absolute neutrophil count (ANC) less than 0.5 × 109 /L, is a serious health problem because it predisposes patients to recurrent bacterial infections. Management radically changed with the discovery that granulocyte colony-stimulating factor (G-CSF) could be used to effectively treat most patients; therapy required regular subcutaneous injections. In the early days of G-CSF therapy, there were concerns that it might somehow overstimulate the bone marrow and cause myelodysplasia (MDS) or acute myeloid leukemia (AML)...
November 18, 2023: Expert Review of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.